Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) — Form 144: Proposed sale of shares
AI-generated summary
Director MICHAEL S BROWN filed to propose the sale of 1,929 shares of common stock with an aggregate market value of $1,579,407.33, acquired through an exercise of stock options on October 30, 2026. The sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services under a trading plan adopted on February 25, 2026.
Key facts
- Seller
- MICHAEL S BROWN
- Relationship
- Director
- Shares to sell
- 1,929
- Market value
- $1,579,407.33
- Approximate sale date
- Oct 30, 2026
- Broker
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Acquired
- Oct 30, 2026 · Exercise of Stock Options
Rule 10b5-1 plan · adopted Feb 25, 2026
More REGN filings
- 144
Filed Oct 30, 2026
- 144
Filed Oct 30, 2026
- 10-Q
Filed Oct 30, 2026
- 8-K
Filed Oct 30, 2026
- 4
Filed Oct 15, 2026
- 144
Filed Oct 14, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.